{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:24:49Z","timestamp":1792686289170,"version":"4.5.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>There is no clear consensus regarding the discontinuation of oral anticoagulants (OACs) after catheter ablation (CA) for atrial fibrillation (AF).<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate thromboembolic and major bleeding events and all-cause death following OAC discontinuation and characteristics associated with patient prognoses after successful CA.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective cohort study included patients without AF recurrence or adverse events 12 months after CA among those undergoing their first CA between January 1, 2006, and December 31, 2021. The study population was divided into groups according to the continuation and discontinuation of OACs at the landmark period of 12 months after CA. Follow-up data were acquired until December 31, 2023, and the study analysis was conducted from January to April 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>OAC discontinuation.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Primary outcomes were thromboembolic and major bleeding events and all-cause death after 12 months. Inverse probability of treatment weighting (IPTW) and propensity score\u2013matched analyses were used to adjust baseline characteristics.<\/jats:p><\/jats:sec>Results<\/jats:title>This study included 1821 patients (mean [SD] age, 63.6 [11.7] years; 1339 men [73.5%]). Overall, 922 patients (50.6%) continued OAC for 12 months, whereas 899 (49.4%) discontinued OAC. During a mean (SD) follow-up of 4.8 (4.0) years, thromboembolic events, major bleeding events, and death occurred in 43 (2.4%), 41 (2.3%), and 71 (3.9%) patients, respectively. After IPTW adjustment, the OAC discontinuation group demonstrated a significantly higher incidence of thromboembolism (incidence rate, 0.86 [95% CI, 0.45-1.35] vs 0.37 [95% CI, 0.22-0.54] per 100 person-years; log-rank P<\/jats:italic>\u2009=\u2009.04) and a lower incidence of major bleeding (incidence rate, 0.10 [95% CI, 0.02-0.19] vs 0.65 [95% CI, 0.43-0.90] per 100 person-years; log-rank P<\/jats:italic>\u2009&amp;lt;\u2009.001) than in the continuation group. In a subgroup analysis, OAC discontinuation was associated with a higher risk of thromboembolism in patients with asymptomatic AF, left ventricular ejection fraction of less than 60%, and left atrial diameter of 45 mm or greater. In contrast, OAC discontinuation was beneficial for reducing major bleeding risks in patients with a HAS-BLED score of 2 or greater. These outcomes were similar in the propensity score\u2013matched analysis using 1100 paired matched patients, except for insignificant differences in thromboembolic events. Differences in mortality between the 2 groups were not statistically significant.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this retrospective cohort study, discontinuation of OACs after successful CA was associated with increased thromboembolic events and decreased bleeding events. The benefits of discontinuing OACs were stratified according to specific characteristics, pending a future prospective randomized study.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.1320","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T17:17:36Z","timestamp":1742577456000},"page":"e251320","source":"Crossref","is-referenced-by-count":26,"title":["Discontinuation of Oral Anticoagulation After Successful Atrial Fibrillation Ablation"],"prefix":"10.1001","volume":"8","author":[{"given":"Tomoya","family":"Iwawaki","sequence":"first","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yanagisawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"},{"name":"Department of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuya","family":"Inden","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Hiramatsu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Yamauchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiichi","family":"Miyamae","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaya","family":"Tachi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Shimojo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiomi","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Murohara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"10","key":"zoi250094r1","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1016\/j.hrthm.2017.05.012","article-title":"2017 HRS\/EHRA\/ECAS\/APHRS\/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation.","volume":"14","author":"Calkins","year":"2017","journal-title":"Heart Rhythm"},{"issue":"7","key":"zoi250094r2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jacc.2014.04.072","article-title":"Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective, multicenter SMART-AF trial.","volume":"64","author":"Natale","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"zoi250094r3","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1056\/NEJMoa1602014","article-title":"Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation.","volume":"374","author":"Kuck","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi250094r4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/eurheartj\/ehu421","article-title":"Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark.","volume":"36","author":"Karasoy","year":"2015","journal-title":"Eur Heart J"},{"issue":"2","key":"zoi250094r5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1001\/jamacardio.2016.4179","article-title":"Assessment of use vs discontinuation of oral anticoagulation after pulmonary vein isolation in patients with atrial fibrillation.","volume":"2","author":"Sj\u00e4lander","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"5","key":"zoi250094r6","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the Diagnosis and Management of Atrial Fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"zoi250094r7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jacc.2009.11.039","article-title":"The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation.","volume":"55","author":"Themistoclakis","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"zoi250094r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2881","article-title":"Risk factors associated with ischemic stroke in Japanese patients with nonvalvular atrial fibrillation.","volume":"3","author":"Okumura","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi250094r9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.106.641225","article-title":"Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation.","volume":"114","author":"Oral","year":"2006","journal-title":"Circulation"},{"issue":"11","key":"zoi250094r10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002597","article-title":"Patterns of anticoagulation use and cardioembolic risk after catheter ablation for atrial fibrillation.","volume":"4","author":"Noseworthy","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"zoi250094r11","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1161\/CIRCEP.111.963231","article-title":"Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score =3: a long-term outcome study.","volume":"4","author":"Saad","year":"2011","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"8","key":"zoi250094r12","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1111\/jce.14052","article-title":"Oral anticoagulation after catheter ablation of atrial fibrillation and the associated risk of thromboembolic events and intracranial hemorrhage: a systematic review and meta-analysis.","volume":"30","author":"Romero","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"4","key":"zoi250094r13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/jce.13822","article-title":"Anticoagulation after catheter ablation of atrial fibrillation: an unnecessary evil? A systematic review and meta-analysis.","volume":"30","author":"Proietti","year":"2019","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"3","key":"zoi250094r14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10840-013-9835-1","article-title":"Discontinuing anticoagulation following successful atrial fibrillation ablation in patients with prior strokes.","volume":"38","author":"Winkle","year":"2013","journal-title":"J Interv Card Electrophysiol"},{"issue":"1","key":"zoi250094r15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1093\/europace\/euz235","article-title":"The safety of discontinuation of oral anticoagulation therapy after apparently successful atrial fibrillation ablation: a report from the Chinese Atrial Fibrillation Registry study.","volume":"22","author":"Yang","year":"2020","journal-title":"Europace"},{"issue":"7","key":"zoi250094r16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/eurheartj\/ehad798","article-title":"Oral anticoagulation after atrial fibrillation catheter ablation: benefits and risks.","volume":"45","author":"Kanaoka","year":"2024","journal-title":"Eur Heart J"},{"issue":"7","key":"zoi250094r17","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1253\/circj.CJ-20-0637","article-title":"JCS\/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias.","volume":"85","author":"Nogami","year":"2021","journal-title":"Circ J"},{"issue":"7","key":"zoi250094r18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.jacep.2020.02.005","article-title":"Periprocedural management of cardiac tamponade during catheter ablation for AF under uninterrupted DOAC and warfarin.","volume":"6","author":"Yanagisawa","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"5","key":"zoi250094r19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jacep.2018.02.013","article-title":"Uninterrupted direct oral anticoagulant and warfarin administration in elderly patients undergoing catheter ablation for atrial fibrillation: a comparison with younger patients.","volume":"4","author":"Yanagisawa","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"issue":"4","key":"zoi250094r20","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"3","key":"zoi250094r21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1161\/CIRCULATIONAHA.104.518837","article-title":"Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence.","volume":"112","author":"Hindricks","year":"2005","journal-title":"Circulation"},{"issue":"17","key":"zoi250094r22","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1093\/eurheartj\/ehx042","article-title":"Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.","volume":"38","author":"Van Gelder","year":"2017","journal-title":"Eur Heart J"},{"issue":"2","key":"zoi250094r23","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/jce.14864","article-title":"Continuous rhythm monitoring-guided anticoagulation after atrial fibrillation ablation.","volume":"32","author":"Pothineni","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"22","key":"zoi250094r24","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1161\/CIRCULATIONAHA.119.042622","article-title":"Cryoballoon or radiofrequency ablation for atrial fibrillation assessed by continuous monitoring: a randomized clinical trial.","volume":"140","author":"Andrade","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"zoi250094r25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamainternmed.2013.1561","article-title":"Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation before and after catheter ablation (DISCERN AF): a prospective, multicenter study.","volume":"173","author":"Verma","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"46","key":"zoi250094r26","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1093\/eurheartj\/ehv513","article-title":"Atrial fibrillation in heart failure: what should we do?","volume":"36","author":"Kotecha","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"zoi250094r27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/CIRCEP.107.754564","article-title":"Atrial remodeling and atrial fibrillation: mechanisms and implications.","volume":"1","author":"Nattel","year":"2008","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"4","key":"zoi250094r28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2459\/JCM.0000000000001608","article-title":"Cardiac imaging correlates and predictors of stroke in patients with atrial fibrillation: a meta-analysis.","volume":"25","author":"Noubiap","year":"2024","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"9","key":"zoi250094r29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/clc.22435","article-title":"The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis.","volume":"38","author":"Zhu","year":"2015","journal-title":"Clin Cardiol"},{"issue":"10","key":"zoi250094r30","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1160\/TH17-07-0478","article-title":"Long-term bleeding risk prediction in \u2018real world\u2019 patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores.","volume":"117","author":"Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"issue":"21","key":"zoi250094r31","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1161\/CIRCULATIONAHA.113.007825","article-title":"Temporal relationship between subclinical atrial fibrillation and embolic events.","volume":"129","author":"Brambatti","year":"2014","journal-title":"Circulation"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2831851\/iwawaki_2025_oi_250094_1741976749.93167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T17:17:38Z","timestamp":1742577458000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2831851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.1320","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}